#bharat biotech

[thenewsfactsnow]

Bharat Biotech and University of Sydney Sign MoU to Advance Academic and Vaccine Research Collaboration

Hyderabad, India, and Sydney, Australia – 28th November 2023 – Bharat Biotech International Limited, a world leading vaccines & bio-therapeutics manufacturer and the University of Sydney Infectious Diseases Institute (Sydney ID) today announced a Memorandum of Understanding (MoU) to advance vaccine research initiatives, strengthen academic-industry partnerships and augment global efforts to…

[ranakaushal]

10th Annual Biotech Industry Conclave on Biotechnology for Humanity: Innovations Shaping a Better World

KIIT School of Biotechnology organized the 10th Biotech Industrial Conclave on “Biotechnology for Humanity: Innovations Shaping a Better World” during 23rd–24thAugust 2024. The conclave, spanning over two days, had enlightening talks, discussion and spirited interactions between experts from the biotech industry, academia, and students to foster collaboration and innovation in the field. During the inaugural session, Dr. Achyuta Samanta, Founder, KIIT & KISS, welcomed all the dignitaries and stressed upon development of strong collaboration between KIIT and biotechnology industry.

Padmashri Dr. Krishna Ella, Founder & Executive Chairman, Bharat Biotech International Limited echoed the need for close interaction between premier educational institutes and the biotech industry for inclusive growth. Dr. Ella, in his keynote address, shared his personal journey in entrepreneurship and innovation, highlighting the challenges and rewards of building a successful biotech company. He emphasized the importance of practical learning experiences for PhD students and the role of the Ella Foundation in supporting their entrepreneurial endeavors. He also stressed upon the need for vaccine development for neglected diseases.

Dr. Shilpa Gadgil, Vice President, Enzene Biosciences Ltd.; Dr. Priyabrata Pattnaik, Dy. Managing Director, Indian Immunologicals Ltd.; Raghavendra P. Rao, Principal Scientist, The Himalaya Drug Company; Dr. Ranendra N. Saha, Chief Scientific Advisor, Biophore; Dr. Sreedharala Venkata Nookaraju, Executive Vice President, Aizant Drug Research Soln. Lt;. and Dr. Prabuddha Kundu, Co-Founder & MD, Premas Biotech discussed about emerging trends in complex therapeutic biomolecules like monoclonal antibodies, novel vaccines, complex protein production processes. Mr. Dushyant Deshmukh, GM-HR, Glenmark Pharmaceuticals; Mr. Hemant Nikam, Sr Director and Head HR, Eisai Pharmaceuticals India; and Mr. Pritesh Bhatia, Associate Director HR, Jubilant Biosys Ltd. discussed about the emerging trends in human resource requirements and how students should prepare themselves to become successful biotechnology professionals.

Mr. Lalit Sisaudia, Vice President of Nutaste Group and Ms. Rosina Panda, Business Manager, Intertek spoke about food safety and the need for precision to address global food security challenges.

Dr. Emili Banerjee, Senior Genetic Counselor, Neuberg Diagnostics, Dr. Raghavendra Goud, Executive Director at PharmNXT Biotech and Mr. Ashish Dubey, Co-Founder and COO, Redcliffe Labs discussed the opportunities in molecular diagnostics in healthcare and how AI driven processes can accelerate disease detection and make healthcare accessible in the remote regions of the country. In the last session, five alumni turned entrepreneurs Mr. Pritam Dhalla, Founder, Larkai Healthcare; Mr. Akashdeep Dan, Co-Founder of Bogmalo Foods and Hospitality; Mr. Prateek Mahapatra, Director of Grow Green Consortium Pvt. Ltd.; Ms. Varsha Biswal, CEO, Trupti Dairy; and Dr. Shailesh Samal, CEO, Inflanova AB shared the memories in KSBT and how it helped them to excel in their areas of passion.

Dr. Mrutyunjay Suar, DG-Research & Innovation, and CEO, KIIT-TBI discussed about start-up innovation system in KIIT and role of Bhubaneswar City Knowledge Cluster in developing fruitful collaboration in the biotechnology sector. Dr. Jnyana Ranjan Mohanty, Registrar and Dr. Srinivas Patnaik, Dean KSBT described the academic initiatives taken for skill development of the students. Dr. Rahul Modak, Convener of the conclave thanked all the dignitaries and participants for their active participation and contribution in the conclave.

[pilcare-nce]

Indirab 2.5IU Injection - Rabies vaccine, Human (2.5IU) - Bharat Biotech - Pilcare Exporter from India to Guyana

Indirab 2.5IU Injection is given to people who are at higher risk of coming in contact with rabies like veterinarians. It is also given to people after an animal bite if the animal could have rabies. If the vaccine is given immediately and appropriately, it is 100 percent effective.

[sudheervanguri]

Bharat Biotech, a globally recognized leader in biotechnology, is offering exciting job opportunities for Sr. Executive, Executive, and Jr. Executive positions in their Production-Bioprocess (Upstream & Downstream) department at their Turkapally, Hyderabad unit. Candidates with M.Sc, B.Tech in Biotechnology, or B.Sc and 2-8 years of experience in bioreactor/fermenter operations are encouraged to apply. Job Overview: Company: Bharat Biotech Department: Production - Bioprocess (Upstream & Downstream) Job Location: Turkapally, Hyderabad Position: Sr. Executive / Executive / Jr. Executive Qualification: M.Sc / B.Tech Biotech / B.Sc Experience: 2-8 years Salary: Negotiable Key Responsibilities: Candidates must have hands on experience in bioreactor/Fermenter. Candidates must have hands on experience in Media preparation system. Hands on experience in downstream process equipment,like ,Chromatography Systems,Filtration,Systems,Ultrafiltration/Diafiltration (UF/DF)Systems,Tangential Flow Filtration (TFF) Systems, Leading and managing the development and optimization of cell culture or fermentation processes to produce therapeutic proteins or biologics. [caption id="attachment_57664" align="aligncenter" width="930"] Bharat Biotech Recruitment - Job vacancies[/caption] Qualifications & Experience: Candidates applying for these positions must have: Educational Requirements: M.Sc/B.Tech in Biotechnology or B.Sc with a relevant focus on bioprocessing or biopharmaceutical production. Experience: 2-8 years of hands-on experience in bioreactors, fermenters, and downstream bioprocess equipment like chromatography systems and ultrafiltration systems. Key Skills: Solid understanding of bioprocessing systems (both upstream and downstream). Experience in the operation, troubleshooting, and maintenance of bioprocess equipment. Knowledge of regulatory requirements for biopharmaceutical manufacturing. How to Apply: Interested candidates can send their updated CVs to careers@bharatbiotech.com, clearly mentioning the position they are applying for in the subject line (e.g., "Applying for Production Executive Position"). Only candidates with 2-8 years of experience will be considered. Fresher applicants will not be considered for these positions.

[gendronrecherche]

Bharat Biotech Unveils Oral Vaccine to Tackle Global Cholera Threat

On Tuesday, Bharat Biotech introduced an oral cholera vaccine aimed at combating the persistent global threat of cholera, particularly in areas with poor sanitation. http://dlvr.it/TChpn2

[civilmentor1]

Current affairs - 30 August 2024

1.Oral Cholera Vaccine (Hillchol) The Hindu Background: Bharat Biotech, in collaboration with Hilleman Labs, has launched Hillchol (BBV131), an oral vaccine for cholera. Global Demand: The vaccine aims to address the global shortage of Oral Cholera Vaccines (OCVs), with a demand exceeding 100 million doses per year. Dosage: Hillchol is administered in two oral doses. Clinical Trials: Phase…

[decentralvaccine]

Oral Cholera Vaccine Launched

India's Bharat Biotech said on Tuesday its oral cholera vaccine cleared a late-stage trial and that it plans a global launch, aiming to make up to 200 million doses a year amid an expanding outbreak of the disease and treatment shortages.

India's drug regulator has approved the vaccine, called Hillchol, and Bharat Biotech will apply for the World Health Organization's pre-qualification to supply to major buyers like the U.N. children's agency UNICEF, the company said.

https://www.reuters.com/business/healthcare-pharmaceuticals/indias-bharat-biotech-says-oral-cholera-vaccine-phase-3-trials-proves-safety-2024-08-27/

[puravibenamastes-blog]

CGU aplica multa de R$ 17,7 mi a laboratório indiano por fraude em venda de vacina contra Covid

A CGU (Controladoria-Geral da União) aplicou multa de R$ 17,7 milhões ao laboratório indiano Bharat Biotech por irregularidades na atuação da empresa no processo de aquisição da vacina Covaxin, destinada ao combate à Covid. A penalidade também inclui suspensão de participação em licitação e impedimento de contratação com a União por um ano. Leia mais (08/16/2024 – 17h55) Artigo Folha de S.Paulo –…

[thenewsfactsnow]

Bharat Biotech firmly condemns baseless reports on COVAXIN Development

Bharat Biotech Condemns Fallacious, misleading reports on COVAXIN , These efforts to discredit our work will not deter us , BB Stated Development #BharatBiotech #Covaxin #Covid19Vaccine

Bharat Biotech today strongly condemned fallacious and misleading information report recently by a foreign media. The company in a statement said -We condemn the targeted narrative against COVAXIN put forth by a select few individuals and groups who have no expertise in vaccines or vaccinology. It is well known that they helped perpetuate misinformation and fake news throughout the pandemic.…

[schoje]

Representantes do consórcio do Nordeste de governadores e da Agência Nacional de Vigilância Sanitária (Anvisa) se reuniram hoje (6) em Brasília para discutir a demanda de importação de lotes da vacina Sputnik V, desenvolvida pelo Instituto Gamaleya, da Rússia, que possui parceria com a empresa brasileira União Química. De acordo com o presidente do consórcio, o governador do Piauí Wellington Dias (PT), a equipe da Anvisa fez uma apresentação técnica, mas houve uma polêmica sobre o pedido de aprovação excepcional do uso do imunizante russo que seria importado pelos governos estaduais. Os estados do Nordeste negociam quase 40 milhões de doses com o governo russo. Mas a conclusão do contrato está condicionada à autorização por parte da autoridade sanitária local, a Anvisa. A Anvisa informou que fará uma visita à Rússia para avaliar as condições de fabricação da Sputnik V. Contudo, os governadores requereram que essa visita não seja uma condição para a permissão excepcional. Semana passada, a Anvisa negou a Certificação de Boas Práticas de Fabricação de Medicamentos ao laboratório indiano Bharat Biotech, que produz a vacina Covaxin, usada contra a covid-19, depois de visita de inspeção, como a que será feita à fabricante russa.  “A decisão da Anvisa é que pode garantir que tenhamos mais vacinas em abril. A intenção é ter 37 milhões de doses compradas pelos estados e mais 10 milhões adquiridas pelo governo federal. Temos 4 mil pessoas que morreram nas últimas 24 horas. Tirar essas vacinas seria um desastre para o Brasil”, disse Wellington Dias, após o encontro.   Conforme o governador do Piauí, a legislação brasileira prevê a validação da autorização excepcional quando um imunizante tiver recebido o aval de autoridade sanitária de uma série de países. No Twitter, o governador do Maranhão, Flávio Dino (PC do B), questionou a posição da Anvisa de ir à Rússia para avaliar o pedido de importação, classificando-a como “inacreditável” diante da situação da pandemia no país. 4.195 mortes. Enquanto isso, a ANVISA nos chamou para uma reunião sobre vacinas, que já dura 3 horas, para dizer que precisam ir à Rússia para avaliar pedido de autorização de importação de vacinas feito pelos Estados. Chega a ser inacreditável. — Flávio Dino ?? (@FlavioDino) April 6, 2021 Uma nova reunião foi marcada para esta quarta-feira para dar continuidade às tratativas sobre a possibilidade de importação da Sputnik V. A reportagem da Agência Brasil solicitou uma avaliação da Anvisa sobre o encontro e aguarda retorno.

[creativeera]

Quantum Sensors Market is estimated to Witness High Growth Owing to Increasing Application

Quantum sensors are cutting-edge devices that use the principles of quantum mechanics to achieve beyond-classical precision, resolution, and sensitivity. Quantum sensors find widespread use in various industries like defense, transportation, healthcare, and consumer electronics. Applications such as quantum communications, quantum computers, atomic clocks, magnetometry, and gravimetry are driving advancements in quantum sensor technologies.

The Quantum Sensors Market is estimated to be valued at US$ 708.6 Mn in 2024 and is expected to reach US$ 1,935.8 Mn by 2031, growing at a compound annual growth rate (CAGR) of 15.4% from 2024 to 2031.

Key Takeaways Key players operating in the Quantum Sensors Market are GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium. Key players are focusing on strategic collaboration and new product launches to strengthen their market position. The key opportunities in the market include developing low-cost sensors for consumer applications and integration of quantum technologies with IoT devices. Many companies are investing heavily in R&D to commercialize quantum sensors for applications like navigation, imaging, and medical diagnostics. The global expansion of the Quantum Sensor Market Growth  is supported by government investments and initiatives. Countries like the US, China, Germany, and the UK are at the forefront of quantum technology development. Increasing adoption across various industries and development of application-specific products will drive the quantum sensors market growth globally over the forecast period. Market Drivers Increasing application of quantum sensors in consumer electronics is a key driver for the market growth. Consumer electronics giants are integrating quantum technologies in smartphones, laptops, and gaming consoles to enhance features like navigation, imaging, and security. Further, quantum sensors offer superior accuracy and precision compared to conventional sensors. This advantage is boosting their demand across various industry verticals like automotive, industrial, healthcare and biomedical. Continuous technological advancements aimed at developing affordable and compact quantum sensors will further propel the market during the forecast period.

PEST Analysis Political: Regulations related to import and export of quantum-based products affect the Quantum Sensors Market Regional Analysis. Government initiatives to develop quantum technologies also impact the industry. Economic: Funding availability from organizations and investments by private firms influence research and development activities. Quantum technologies find applications in industries like healthcare, defense etc boosting their demand. Social: Wide usage of consumer electronics and other devices increases need for quantum sensors. Growing awareness about advanced technologies creates scope for further applications of quantum sensing. Technological: Development of sophisticated infrastructure and miniaturized devices aids design of cutting-edge quantum sensors. Integration of quantum systems with classical technologies expands scope of applications. Advances in fields like quantum computing and communications fuel technological progress. North America accounts for the largest share of the quantum sensors market in terms of value. Presence of major players, strong government support for research, and high adoption of advanced quantum technologies drive the regional market. Asia Pacific is expected to witness the fastest growth during the forecast period. Rising investments in R&D, increasing demand from end-use industries, and government initiatives to develop indigenous quantum technologies stimulate market growth in the region. Countries like India, Japan, and China are focusing on various projects involving quantum computing, sensing and networking.

Get more insights on Quantum Sensors Market

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )

[pilcare-nce]

Biopolio Vaccine - Polio Vaccine - Bharat Biotech - Pilcare Exporter from India to Guyana

Biopolio Vaccine is an inactivated polio vaccine (IPV). It protects against the virus that causes polio. Polio is a crippling and potentially deadly infectious disease that causes paralysis (cannot move body parts).

[pharmawalksjobs]

Job opportunity for Production department at Bharat biotech

Bharat Biotech International Limited is a versatile biotechnology firm that focuses on research, development, and production of vaccines and biotherapeutics. The company is dedicated to creating advanced vaccines and bio-therapeutics through groundbreaking and cooperative research efforts. BBIL’s cutting-edge manufacturing facility stands as the largest in the Asia-Pacific region. Join Bharat…

[bslethitrucphuong]

10 Loại Vắc Xin Bạch Hầu Phổ Biến Cho Trẻ Em Và Người Lớn Tại Việt Nam

Bạch hầu là bệnh truyền nhiễm nguy hiểm do vi khuẩn gây ra, có thể dẫn đến biến chứng nặng, thậm chí tử vong. Vắc xin bạch hầu đóng vai trò quan trọng trong việc phòng ngừa hiệu quả căn bệnh này. Bài viết này sẽ cung cấp thông tin về 10 loại vắc xin bạch hầu phổ biến được lưu hành tại Việt Nam dành cho trẻ em và người lớn.

Xem thêm: https://vnvc.vn/vac-xin-bach-hau/

1. Vắc xin 5 trong 1:

Phòng ngừa 5 bệnh: bạch hầu, ho gà, uốn ván, viêm gan B và viêm phổi do vi khuẩn Hib.

Tiêm cho trẻ em từ 2, 3, 4 tháng tuổi, mỗi mũi cách nhau 30 ngày.

Thuộc chương trình tiêm chủng mở rộng của Bộ Y tế, được tiêm miễn phí.

2. Vắc xin 6 trong 1:

Phòng ngừa 6 bệnh: bạch hầu, ho gà, uốn ván, bại liệt, viêm gan B và viêm phổi do vi khuẩn Hib.

Tiêm cho trẻ em từ 2, 3, 4 tháng tuổi và 16 - 18 tháng tuổi.

Vắc xin dịch vụ, có chi phí.

3. Vắc xin bạch hầu - ho gà - uốn ván (DPT):

Phòng ngừa 3 bệnh: bạch hầu, ho gà và uốn ván.

Tiêm cho trẻ em từ 6 tuần tuổi, mỗi mũi cách nhau 4 - 6 tuần.

Thuộc chương trình tiêm chủng mở rộng, được tiêm miễn phí.

4. Vắc xin bạch hầu - uốn ván (DT):

Phòng ngừa 2 bệnh: bạch hầu và uốn ván.

Tiêm nhắc cho trẻ em từ 5 - 7 tuổi và người lớn.

Vắc xin dịch vụ, có chi phí.

5. Vắc xin bạch hầu - ho gà - uốn ván giảm liều (Tdap):

Phòng ngừa 3 bệnh: bạch hầu, ho gà và uốn ván với liều lượng thấp hơn so với DPT.

Tiêm nhắc cho thanh thiếu niên từ 11 - 18 tuổi và người lớn.

Vắc xin dịch vụ, có chi phí.

6. Vắc xin bạch hầu - uốn ván (TT):

Phòng ngừa 2 bệnh: bạch hầu và uốn ván.

Tiêm nhắc cho người lớn từ 19 tuổi trở lên, mỗi 10 năm một lần.

Vắc xin dịch vụ, có chi phí.

7. Vắc xin Infanrix Hexa:

Vắc xin 6 trong 1, sản xuất bởi hãng Sanofi Pasteur.

Tiêm cho trẻ em từ 2, 3, 4 tháng tuổi và 16 - 18 tháng tuổi.

Vắc xin dịch vụ, có chi phí.

8. Vắc xin Hexaxim:

Vắc xin 6 trong 1, sản xuất bởi hãng GlaxoSmithKline.

Tiêm cho trẻ em từ 2, 3, 4 tháng tuổi và 16 - 18 tháng tuổi.

Vắc xin dịch vụ, có chi phí.

9. Vắc xin Pentavac:

Vắc xin 5 trong 1, sản xuất bởi hãng Bharat Biotech.

Tiêm cho trẻ em từ 6, 10, 14 tuần tuổi và 16 - 18 tháng tuổi.

Vắc xin dịch vụ, có chi phí.

10. Vắc xin Adacel:

Vắc xin Tdap, sản xuất bởi hãng Sanofi Pasteur.

Tiêm nhắc cho thanh thiếu niên từ 11 - 18 tuổi và người lớn.

Vắc xin dịch vụ, có chi phí.

Lưu ý:

Lịch tiêm chủng có thể thay đổi tùy theo độ tuổi, sức khỏe và tình trạng tiêm chủng trước đây của mỗi người.

Nên tham khảo ý kiến bác sĩ trước khi tiêm bất kỳ loại vắc xin nào.

Ngoài 10 loại vắc xin kể trên, còn có một số loại vắc xin bạch hầu khác được lưu hành tại Việt Nam. Việc lựa chọn loại vắc xin phù hợp sẽ phụ thuộc vào nhiều yếu tố, bao gồm độ tuổi, tình trạng sức khỏe và nhu cầu của mỗi người.

[rohanisblog]

India Specialty Drug Distribution Market generated a revenue of US$ 2,045.35 million in 2022 and is estimated to reach a valuation of US$ 5,997.7 million by 2031 at a CAGR of 12.93% during the forecast period 2023–2031.

Key Players in the Market Report 

Aark Pharmaceuticals

Astellas Pharma India Pvt. Ltd.

Aurobindo Pharmaceuticals

Arlak Biotech

Bharat Serums and Vaccines Limited

Biotic Healthcare

Cipla

D.Vijay Pharma

Dr. Reddy’s Laboratories Ltd

Divis Laboratories

Feron Healthcare

Gaia Pharmaceutical Trade

Glenmark Pharmaceuticals

GNova Biotech

Ikris Pharma

IMS Medi

Jay-Pharma

Lupin

Meher Distributors Pvt. Ltd.

Merck & Co., Inc.

Novartis AG

Novacare

Pax Healthcare

Prime Health

Sanify Healthcare

Serum Institute of India Pvt. Ltd.

Sun Pharmaceutical Industries Ltd.

Servocare Lifesciences

Shubham Pharmaceutical

Swisschem Healthcare

Torrent Pharmaceuticals

Vardhman Health Specialities Pvt. Ltd.

Zydus Lifesciences Limited

Intas Pharmaceuticals Ltd.

3S Corporation

Other Prominent Players